Log-In
|
Home
|
E-mail Alerts
|
My Headlines
|
Portfolio
Home
Menu
JOIN
SI Premium
Ratings
Mergers
Earnings
Dividends
IPOs
Hedge Funds
Premium Letters
Send a Tip
API/Data
JOIN
SI Premium
Full Feed View
Headline View
SI Premium Squawk Box
Alerts
Custom Headlines
Upgrade Your Current Account
API
Calendars
Co. NDR/Event Calendar
Dividend Calendar
Earnings Calendar
Event Driven
FDA Calendar
Investor Conferences
IPO Calendar
Merger Arb
Ratings Calendar
Stock Split Calendar
Ratings
Analyst Comments
Hot Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Credit Ratings
Downgrade News
Hot Downgrades
New Coverage News
Hot New Coverage
Upgrade News
Hot Upgrades
More...
Mergers
Merger News
Hot M&A News
Private Equity
Rumors
SPAC News
Spinoffs
Merger Arbitrage
Event Driven
2021 Top M&A Deals
Top 50 Takeover Targets
More...
Earnings
Earnings Calendar
Earnings News
Hot Earnings
Guidance
Hot Guidance
Conference Calls
Earnings History Search
More...
Dividends
Dividend Calendar
Dividend News
Hot Dividends
Dividend Hike
Special Dividends
Stock Buybacks
Hot Stock Buybacks
Stock Splits
More...
IPOs
IPO News
Hot IPOs
Equity Offerings
Recent IPOs
Upcoming IPOs
2021 Top IPOs
More...
Hedge Funds
13D
13F
13G
Hedge Funds News
Hot Insider Trades
Insider Trades
More...
Premium Letters
Pulse Picks
Stealth Growth Insider
Send a Tip
API/Data
QUICK LINKS :
Goldman Sachs Conviction Buy List
Warren Buffett News
Elliott Management News
Follow @Street_Insider
Premium Content
News Feeds
Full Feed $
Today's Headlines
Custom Headlines
My Portfolio Headlines
Entities
Company News
AI $
Board Changes $
Corporate News $
Hot Corp. News $
Litigation $
Management Changes $
Hot Mgmt Changes $
Management Comments $
Private Company News $
Retail Sales
Dividends/Sh. Returns
Dividends $
Hot Dividends $
Dividend Cut $
Dividend Hike $
Special Dividends $
Stock Buybacks $
Hot Buybacks $
Stock Splits $
EPS
Conference Calls $
Earnings $
Hot Earnings $
Guidance $
Hot Guidance $
ETFs
ETFs
FDA
FDA $
Hot FDA News $
Insiders/Hedge Funds
13Ds $
13Fs $
13Gs $
Hedge Funds $
Hot Hedge Fund News $
Insider Trades $
Hot Insider Trades $
M&A
Mergers and Acquisitions $
Hot M&A $
Private Equity $
Rumors $
Spinoffs $
Macro
Commodities $
Cryptocurrency
Economic Data $
Fed $
Forex
Market Check
Market Movers
Hot List $
Hot List Pro $
Index Changes $
Insiders' Blog
Momentum Movers $
Options $
Option EPS Action $
Short Sales $
Special Reports $
Technicals $
Trading Halts $
Trader Talk $
Offerings
Equity Offerings $
IPOs $
Hot IPOs $
SPAC $
Other
Contributors
General News
Politics
Life Enjoyed
Rating Changes
Analyst Comments $
Hot Comments $
Analyst EPS Change $
Analyst EPS View $
Analyst PT Change $
Credit Ratings
Downgrades $
Hot Downgrades $
Intl Ratings $
New Coverage $
Hot New Coverage $
Upgrades $
Hot Upgrades $
Unfiltered Feeds
8K
Press Releases
ACCESS Newswire
Binary News Network
Bitwire
Business Wire
DWPR
Evertise Financial
EZ Newswire
The Financial Capital
First Publisher
FNMedia
GetNews
Globe Newswire
Globe PR Wire
Insights News Wire
Investor Brand Network
KeyCrew
MarketMediaWire
Media OutReach
NewMediaWire
Newsfile
Newsworthy
Pinion Newswire
Press Services
PRNewswire
Rev Up Marketer
Send2Press
Shan News Network
Wall Street PR
WorldNewsWire
Investing
SEC Filings
Reuters
Special Reports
After-Hours Stock Movers: NKE, BE, STZ, RIG
After-Hours Stock Movers: AVAV, PRAX, VSH, CNXC, SHAZ
Comcast, Viridian Therapeutics jump premarket; Doximity slips
Market Snapshot
Nasdaq
S&P 500
Nasdaq
15000.33
+57.68
(+0.39%)
S&P 500
4486.55
+7.02
(+0.16%)
Quotes delayed at least 20 mins.
Send to a Friend
Font Size:
Increase
Decrease
Twitter
http://www.twitter.com
Twitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
Login to help us fill in information about this entity.
MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatology
Nov 2, 2016 02:34AM
Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
Mar 9, 2015 07:00AM
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
Mar 9, 2015 02:39AM
